Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
Recruiting
Observational Study
Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis Without Nasal Polyps
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 80 (estimated)
- Sponsor
- Medical University of Vienna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators aim to investigate two major so far unresolved topics in CRSwNP research: (1) Thorough functional and molecular characterisation of barrier function in patients suffering from CRSsNP and CRSwNP and (2) effect of dupilumab treatment on barrier function in polyp patients. This will be achieved in patient-derived samples by employing measurement of barrier function in primary cell c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18-99 years of age
* Willingness to participate in the study
* Suffer from chronic rhinosinusitis defined as in EPOS 2020 criteria, see main text
* Group 1 (n=20, CRSsNP): Absence of nasal polyps
* Group 2 (N=60, CRSwNP): Presence of nasal polyps as confirmed by endoscopy or C…
Contacts
No contact information available.